On tonight’s MAD MONEY on CNBC, Jim Cramer discussed Regenron (REGN) as one where he had interviewed the CEo of the company back when he started doing MAD MONEY. This went fom $5 to $24 even though it still doesn’t have a product on the market. He wanted to review it now that it has gone back down close to $18.00. One that he likes in the sector just as much as REGN back when is Nastech Pharma (NSTK). NSTK loses money and it lost Merck on the obesity study and for a while it only issued press releases. The stock is thought of as a joke, but now you must own it if you are a biotech speculator. He reviewed teh company for 5 days before reviewing it. It has $90M cash and has compounds for RNA Interference tests, obesity, osteoporosis, and others. None of the products are commercial yet but it has plenty of cash. When it got crushed they left the street with no reason to own the stock. At the end of the year it styopped issuing press releases and now the main seller has finally cleaned out of the stock. Cramer thinks the compounds may actually work and Wall Street doesn’t know it. They have also hired a great industry person to help it work on compounds.
Jon C. Ogg
March 16, 2007
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
